oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes SELECT Trial Oral Semaglutide and Cardiovascular Outcomes

Description

In that environment, Lillys move reads like a retention tool to make the product easier to live with and reduce the little hassles that prompt patients to pause or quit

Lilly noted that some TRIUMPH-4 dropouts were people who lost more weight than they intended, which would inflate the figure compared with strictly tolerance-driven dropouts

The protein target decreases accordingly, and the medication-specific guidance is hidden, but the calorie targets and balanced-plate methods work just the same

Oral semaglutide is generally considered for individuals with a Body Mass Index (BMI) of 30 or higher, or a BMI of 27 or higher when accompanied by weight-related health concerns

Before starting GLP-1 medications: Ensure you've had a recent diabetic eye screening (within the past 12 months) Discuss your retinopathy status with your prescribing clinician If you have known retinopathy, consider ophthalmology review before initiation Understand that gradual dose titration may help avoid very rapid changes in blood glucose, which is a general principle in diabetes management During treatment: Attend all scheduled diabetic eye screening appointments without fail If you have pre-existing retinopathy, your diabetes team may consider more frequent monitoring based on your individual clinical situation Control blood pressure to target levels (below 140/90 mmHg, or below 130/80 mmHg if you have kidney, eye or cerebrovascular damage, if tolerated) Maintain good overall glycaemic control whilst avoiding excessively rapid HbA1c reductions when possible Stop smoking if applicable, as tobacco significantly worsens diabetic eye disease Manage cholesterol levels according to NICE guidance for cardiovascular risk reduction Communicate openly with your healthcare team about any visual symptoms, even if they seem minor